Revolution Medicines, Inc. (RVMD)

業務介紹

Revolution Medicines, Inc.（Revolution Medicines，Inc.）是一家臨床階段的精準腫瘤學公司，專注於開發抑制RAS依賴性癌症的前沿靶點的治療方法。該公司正在開發RMC-4630，一種SHP2抑制劑，目前正在進行用於固體腫瘤治療的1/2期臨床試驗，如婦科和結直腸癌腫瘤。它還開發了RMC-5845，一種選擇性抑制劑，用於抑制細胞中將RAS（OFF）轉換為RAS（ON）的蛋白質SOS1；以及RMC-5552，一種超活化的選擇性抑制劑，用於腫瘤中的mTORC1信號傳遞。此外，該公司還在開發RMC-6291，一種突變選擇性抑制劑，用於KRASG12C（ON）和NRASG12C（ON）；以及RMC-6236，一種多種RAS（ON）變異體的RAS選擇性抑制劑。此外，它還開發了針對KRASG13C（ON）和KRASG12D（ON）的RAS（ON）抑制劑。該公司與Sanofi簽訂了合作協議，共同研究和開發SHP2抑制劑，包括RMC-4630。Revolution Medicines，Inc.成立於2014年，總部位於加利福尼亞州Redwood City。

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

公司網址

https://www.revmed.com